Earnings release
Page 1
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited ( the " Stock Exchange " ) take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . GenScript BioTechCorp . Genscript Biotech Corporation ( Incorporated in the Cayman Islands with limited liability ) ( Stock code : 1548 ) ANNOUNCEMENT OF UNAUDITED CONSOLIDATED INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026 2026 INTERIM RESULTS HIGHLIGHTS 2026 Six months ended 30 June 2025 2025 Reported / Underlying Reported Underlying Underlying Basis Change ( Note 1 ) US $ ' 000 US $ ' 000 US $ ' 000 % Revenue Gross profit 404,216 317,413 518,773 27.3 206,711 139,707 320,631 48.0 Adjusted net profit 62,523 20,614 177,973 203.3 Loss after income tax ( 129,344 ) ( 181,906 ) ( 24,547 ) 28.9 -Profit from GenScript core business 25,557 11,792 169,151 116.7 -Share of loss from Legend ( book basis ) -Non - cash equity accounting impact on ( 9,945 ) ( 106,973 ) ( 106,973 ) 90.7 interest in Legend ( 144,956 ) ( 86,725 ) ( 86,725 ) ( 67.1 ) During the Reporting Period , the Group's underlying business achieved robust growth . The revenue of the Group for the Reporting Period was approximately US $ 404.2 million , representing a YoY increase of 27.3 % on an underlying basis . During the Reporting Period , the gross profit of the Group was approximately US $ 206.7 million , representing a YoY increase of 48.0 % on an underlying basis . The adjusted net profit ( Note 2 ) of the Group for the Reporting Period was approximately US $ 62.5 million , representing a YoY increase of 203.3 % on an underlying basis . The Group's core business recorded a net profit of approximately US $ 25.6 million for the Reporting Period , representing a YoY increase of 116.7 % from approximately US $ 11.8 million for the Prior Period on an underlying basis . The Group's “ core business ” refers to the results of the Group excluding the equity accounting impact from Legend . 1